Welcome to LookChem.com Sign In|Join Free

CAS

  • or

112885-42-4

Post Buying Request

112885-42-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

112885-42-4 Usage

Description

Mosapride is an agonist of the serotonin (5-HT) receptor subtype 5-HT4 (Ki = 69.9 nM). It is selective for 5-HT4 over 5-HT1, 5-HT2, dopamine D2, and α1- and α2-adrenergic receptors but acts as a partial antagonist at 5-HT3 (Ki = 1,189 nM). It induces relaxation of precontracted rat esophageal thoracic muscularis mucosa preparations and enhances electrically evoked contractions in isolated guinea pig ileum (EC50s = 208.4 and 73.2 nM, respectively). Mosapride (0.5 and 1 mg/kg, i.v.) increases antral and duodenal, but not ileal or colonic, motility in conscious dogs. It also increases gastric emptying in rats when administered at doses ranging from 0.03 to 30 mg/kg.

Uses

Different sources of media describe the Uses of 112885-42-4 differently. You can refer to the following data:
1. As a selective SR-4 activator and a SR-3 inhibitor, Mosapride(Mosapride citrate) is a gastroprokinetic agent that acts as a selective 5HT4 agonist which accelerates gastric emptying and is used for the treatment of acid reflux, irritable bowel syndrome and functional dyspepsia.
2. A selective SR-4 activator and a SR-3 inhibitor
3. Mosapride Citrate is a selective SR-4 activator and a SR-3 inhibitor.

Biological Activity

5-HT 4 receptor agonist and 5-HT 3 receptor antagonist. Displays no activity at D 2 , α 1 , α 2 , 5-HT 1 and 5-HT 2 receptors. Gastroprokinetic agent; increases gastric emptying in rats and stimulates gastric motor actvity in conscious dogs.

Check Digit Verification of cas no

The CAS Registry Mumber 112885-42-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,8,8 and 5 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 112885-42:
(8*1)+(7*1)+(6*2)+(5*8)+(4*8)+(3*5)+(2*4)+(1*2)=124
124 % 10 = 4
So 112885-42-4 is a valid CAS Registry Number.
InChI:InChI=1/C21H25ClFN3O3.C6H8O7.2H2O/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10;;/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);2*1H2

112885-42-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Mosapride citrate

1.2 Other means of identification

Product number -
Other names 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide,2-hydroxypropane-1,2,3-tricarboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:112885-42-4 SDS

112885-42-4Synthetic route

mosapride
112885-41-3

mosapride

citric acid
77-92-9

citric acid

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
In ethanol; water at 70 - 75℃; for 0.5h; Temperature;97.2%
at 80 - 110℃; for 0.5h; Product distribution / selectivity;95.45%
In ethanol; water at 50℃; for 1h; Solvent; Temperature;94.7%
In ethanol; water at 20℃; for 2h;89%
4-acetylamino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide
112885-34-4

4-acetylamino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide

citric acid
77-92-9

citric acid

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
In methanol; water at 50 - 65℃; Temperature;88.7%
(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide dihydrochloride

(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide dihydrochloride

citric acid
77-92-9

citric acid

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Stage #1: (RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide dihydrochloride With sodium hydroxide In dichloromethane; water for 0.5h; Heating / reflux;
Stage #2: citric acid In water at 0℃; for 0.5h; Heating / reflux;
88%
mosapride
112885-41-3

mosapride

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
With citric acid In water at 0℃; Heating / reflux;86%
(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide trifluoroacetate
636582-76-8

(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide trifluoroacetate

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Stage #1: (RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide trifluoroacetate With sodium hydroxide In dichloromethane; water
Stage #2: With citric acid In water
83%
4-(4-fluorobenzyl)-2-aminomethylmorpholine sulfate

4-(4-fluorobenzyl)-2-aminomethylmorpholine sulfate

C13H16ClNO4

C13H16ClNO4

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
2: methanol; water / 50 - 65 °C
View Scheme
4-(4-fluorobenzyl)-2-aminomethylmorpholine hydrochloride

4-(4-fluorobenzyl)-2-aminomethylmorpholine hydrochloride

C13H16ClNO4

C13H16ClNO4

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
2: methanol; water / 50 - 65 °C
View Scheme
4-(4-fluorobenzyl)-2-aminomethylmorpholine phosphate

4-(4-fluorobenzyl)-2-aminomethylmorpholine phosphate

C13H16ClNO4

C13H16ClNO4

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
2: methanol; water / 50 - 65 °C
View Scheme
C12H17FN2O4S

C12H17FN2O4S

C13H16ClNO4

C13H16ClNO4

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
2: methanol; water / 50 - 65 °C
View Scheme
sodium p-aminosalicylate
133-10-8

sodium p-aminosalicylate

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: water / 4 h / 45 °C
2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
5: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 5 steps
1: water / 4 h / 45 °C
2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
5: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 5 steps
1: water / 4 h / 45 °C
2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
5: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 5 steps
1: water / 4 h / 45 °C
2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
5: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 5 steps
1: water / 4 h / 45 °C
2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
5: methanol; water / 50 - 65 °C
View Scheme
4-acetamidosalicylic acid
50-86-2

4-acetamidosalicylic acid

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
2: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
3: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
2: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
3: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
2: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
3: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
2: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
3: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C
2: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
3: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4: methanol; water / 50 - 65 °C
View Scheme
4-fluorobenzaldehyde
459-57-4

4-fluorobenzaldehyde

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: sodium tetrahydroborate / methanol / 4 h / 65 °C
2.1: 3 h / 70 - 80 °C
2.2: 2.5 h / 70 - 145 °C
2.3: 1.5 h
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1.1: sodium tetrahydroborate / methanol / 4 h / 65 °C
2.1: 3 h / 70 - 80 °C
2.2: 2.5 h / 70 - 145 °C
2.3: 1.5 h
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1.1: sodium tetrahydroborate / methanol / 4 h / 65 °C
2.1: 3 h / 70 - 80 °C
2.2: 2.5 h / 70 - 145 °C
2.3: 1.5 h
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1.1: sodium tetrahydroborate / methanol / 4 h / 65 °C
2.1: 3 h / 70 - 80 °C
2.2: 2.5 h / 70 - 145 °C
2.3: 2 h
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 4 steps
1.1: sodium tetrahydroborate / methanol / 4 h / 65 °C
2.1: 3 h / 70 - 80 °C
2.2: 2.5 h / 70 - 145 °C
3.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
4.1: methanol; water / 50 - 65 °C
View Scheme
4-acetylamino-2-ethoxy-benzoic acid ethyl ester
2486-67-1

4-acetylamino-2-ethoxy-benzoic acid ethyl ester

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
2: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
2: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
2: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
2: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C
2: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3: methanol; water / 50 - 65 °C
View Scheme
C13H16ClNO4

C13H16ClNO4

2-aminomethyl-4-(4-fluoro-benzyl) morpholine
112914-13-3

2-aminomethyl-4-(4-fluoro-benzyl) morpholine

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
2: methanol; water / 50 - 65 °C
View Scheme
2-(4-fluoro-benzyl-amino)-ethanol
22116-33-2

2-(4-fluoro-benzyl-amino)-ethanol

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 3 h / 70 - 80 °C
1.2: 2.5 h / 70 - 145 °C
1.3: 1.5 h
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1.1: 3 h / 70 - 80 °C
1.2: 2.5 h / 70 - 145 °C
1.3: 1.5 h
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1.1: 3 h / 70 - 80 °C
1.2: 2.5 h / 70 - 145 °C
1.3: 1.5 h
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1.1: 3 h / 70 - 80 °C
1.2: 2.5 h / 70 - 145 °C
1.3: 2 h
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3.1: methanol; water / 50 - 65 °C
View Scheme
Multi-step reaction with 3 steps
1.1: 3 h / 70 - 80 °C
1.2: 2.5 h / 70 - 145 °C
2.1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C
3.1: methanol; water / 50 - 65 °C
View Scheme
2-fluoro-4-nitro-benzoic acid methyl ester
392-09-6

2-fluoro-4-nitro-benzoic acid methyl ester

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: ethanol / 4 h / 40 °C
2: iron(III) chloride; N-chloro-succinimide / N,N-dimethyl-formamide / 4 h / 50 °C
3: N,N-dimethyl-formamide / 6 h / 100 °C
4: iron; ammonium chloride / ethanol; water / 5 h / Reflux
5: ethanol; water / 2 h / 20 °C
View Scheme
Multi-step reaction with 5 steps
1: ethanol / 4 h / 40 °C
2: iron(III) chloride; N-chloro-succinimide / N,N-dimethyl-formamide / 4 h / 50 °C
3: triethylamine / N,N-dimethyl-formamide / 6 h / 100 °C
4: iron; ammonium chloride / ethanol; water / 5 h / Reflux
5: ethanol; water / 2 h / 20 °C
View Scheme
2-fluoro-4-nitrobenzoic acid
403-24-7

2-fluoro-4-nitrobenzoic acid

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: sulfuric acid / 4 h / Reflux
2: ethanol / 4 h / 40 °C
3: iron(III) chloride; N-chloro-succinimide / N,N-dimethyl-formamide / 4 h / 50 °C
4: N,N-dimethyl-formamide / 6 h / 100 °C
5: iron; ammonium chloride / ethanol; water / 5 h / Reflux
6: ethanol; water / 2 h / 20 °C
View Scheme
Multi-step reaction with 6 steps
1: sulfuric acid / 4 h / Reflux
2: ethanol / 4 h / 40 °C
3: iron(III) chloride; N-chloro-succinimide / N,N-dimethyl-formamide / 4 h / 50 °C
4: triethylamine / N,N-dimethyl-formamide / 6 h / 100 °C
5: iron; ammonium chloride / ethanol; water / 5 h / Reflux
6: ethanol; water / 2 h / 20 °C
View Scheme
methyl 2-ethoxy-4-nitrobenzoate
24091-87-0

methyl 2-ethoxy-4-nitrobenzoate

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: iron(III) chloride; N-chloro-succinimide / N,N-dimethyl-formamide / 4 h / 50 °C
2: N,N-dimethyl-formamide / 6 h / 100 °C
3: iron; ammonium chloride / ethanol; water / 5 h / Reflux
4: ethanol; water / 2 h / 20 °C
View Scheme
Multi-step reaction with 4 steps
1: iron(III) chloride; N-chloro-succinimide / N,N-dimethyl-formamide / 4 h / 50 °C
2: triethylamine / N,N-dimethyl-formamide / 6 h / 100 °C
3: iron; ammonium chloride / ethanol; water / 5 h / Reflux
4: ethanol; water / 2 h / 20 °C
View Scheme
2-ethoxy-4-nitro-5-chlorobenzoic acid methyl ester

2-ethoxy-4-nitro-5-chlorobenzoic acid methyl ester

mosapride citrate
112885-42-4

mosapride citrate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: triethylamine / N,N-dimethyl-formamide / 6 h / 100 °C
2: iron; ammonium chloride / ethanol; water / 5 h / Reflux
3: ethanol; water / 2 h / 20 °C
View Scheme
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 6 h / 100 °C
2: iron; ammonium chloride / ethanol; water / 5 h / Reflux
3: ethanol; water / 2 h / 20 °C
View Scheme
mosapride citrate
112885-42-4

mosapride citrate

mosapride
112885-41-3

mosapride

mosapride citrate
112885-42-4

mosapride citrate

citric acid
77-92-9

citric acid

A

C27H31ClFN3O9

C27H31ClFN3O9

B

C27H31ClFN3O10

C27H31ClFN3O10

Conditions
ConditionsYield
at 105℃; for 17h;

112885-42-4Downstream Products

112885-42-4Related news

Effect of Mosapride citrate (cas 112885-42-4) Hydrate on the Colon Cleansing Action of Polyethylene Glycol Electrolyte Lavage Solution (PEG-ELS) in Guinea Pigs08/04/2019

.Polyethylene glycol electrolyte lavage solution (PEG-ELS) is widely used for colon cleansing prior to colonoscopy and colonic surgery. It has recently been shown that coadministration of PEG-ELS and mosapride citrate hydrate (mosapride), a selective 5-HT4–receptor agonist, is clinically useful...detailed

Liquid chromatography–tandem mass spectrometric method for determination of Mosapride citrate (cas 112885-42-4) in equine tissues08/03/2019

A simple method for determination of mosapride citrate and its metabolite, des-p-fluorobenzyl mosapride (M-1), in equine muscle, liver, kidney, adipose tissue and intestine by liquid chromatography–tandem mass spectrometry has been developed. (±)-4-Amino-5-chloro-2-ethoxy-N-[[4-(2-chlorobenzyl...detailed

Dual Role of Mosapride citrate (cas 112885-42-4) Hydrate on the Gastric Emptying Evaluated by the Breath Test in Conscious Rats08/01/2019

.Mosapride citrate hydrate (mosapride) has been known to act as a 5-HT4 agonist and to enhance gastric emptying. However, its mode of action, such as time course and dosage effect, on gastric emptying has not been clarified. This study aimed to clarify these points by the breath test using [1-13...detailed

Development of a novel combination tablet containing trimebutine maleate and Mosapride citrate (cas 112885-42-4) for the treatment of functional dyspepsia07/31/2019

To develop a novel combination tablet which contained 100 mg trimebutine maleate and 5 mg mosapride citrate (TMCT) for the treatment of functional dyspepsia, the wet granulation method was used to prepare TMCTs with various amounts of diluents and stabilizers. The levels of impurities, the stabi...detailed

Spectrophotometric determination of carbamazepine and Mosapride citrate (cas 112885-42-4) in pure and pharmaceutical preparations07/30/2019

Simple, rapid and sensitive spectrophotometric methods were developed for the determination of carbamazepine and mosapride citrate drugs in pure and pharmaceutical dosage forms. These methods are based on ion pair and charge transfer complexation reactions. The first method is based on the react...detailed

Dose-dependent effects of Mosapride citrate (cas 112885-42-4) on duodenal and cecal motility in donkeys (Equus asinus)07/29/2019

Prokinetic drugs are used for the management of gastrointestinal motility disorders in horses; however, little is known about their efficacy in donkeys. Therefore, the aim of the present study was to evaluate the effect of different doses of mosapride citrate on duodenal and cecal motility in no...detailed

The effect of Mosapride citrate (cas 112885-42-4) on constipation in patients with diabetes07/28/2019

ObjectiveConstipation is one of the most common gastrointestinal complications suspected to degrade the quality of life in diabetic patients. Mosapride citrate is a novel selective 5-HT4 receptor agonist, which enhances gastric emptying and motility in the upper gastrointestinal tract facilitati...detailed

Comparison of the effects of esomeprazole plus Mosapride citrate (cas 112885-42-4) and botulinum toxin A on vocal process granuloma07/27/2019

ObjectivesVocal process granulomas have a high tendency for persistence despite many treatment alternatives. Anti-reflux medications or botulinum toxin A injections are the main current therapies. There are no studies that compare the effects on vocal process granuloma of proton pump inhibitors ...detailed

Molecularly imprinted polymers based biomimetic sensors for Mosapride citrate (cas 112885-42-4) detection in biological fluids07/26/2019

Computational modeling was applied to study the intermolecular interactions in the pre-polymerization mixture and find a suitable functional monomer to use in the design of a new molecularly imprinted polymer (MIP) for mosapride citrate which is considerably a large molecule (as the citrate ion ...detailed

112885-42-4Relevant articles and documents

Synthesis method of mosapride citrate

-

, (2020/07/15)

The invention provides a preparation method of mosapride citrate, namely 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorophenyl)morpholin-2-yl)methyl)benzamide citrate. The method provided by the invention has the advantages of cheap and easily available raw materials, short reaction steps, high yield, simple post-treatment and the like, reduces the cost, has certain technical advantages, and is suitablefor large-scale industrial production.

Citric acid mosapride intermediate product and application

-

, (2018/09/08)

The invention belongs to the field of medical chemistry synthesis, and provides a preparation method of citric acid mosapride intermediate product IV 4-[(4-fluorophenyl)methyl]-2-morpholinemethanaminesalt and citric acid mosapride. The 2-(4-fluorobenzoamido)ethanol and 1H-Isoindole-1,3(2H)-dione,2-(2-oxiranylmethyl) are taken as raw materials, and the intermediate product IV 4-[(4-fluorophenyl)methyl]-2-morpholinemethanamine salt is obtained after acid treating is conducted; the intermediate product IV and an intermediate V 2-oxethyl-4-acetamido-5-Chlorobenzoic acid ethyl ester compounds aretaken as raw materials, dichloromethane is taken as a solvent, and EDCI and DMAP are taken as catalysts to prepare mosapride salt; the mosapride salt is reacted with citric acid aqueous solution to prepare citric acid mosapride. The intermediate product has the advantages that products are high in yield, raw materials are easy to obtain, the production cost is low, and the intermediate product issuitable for industrialized production.

HIGHLY PURE MOSAPRIDE CITRATE DIHYDRATE AND PROCESSES FOR ITS PREPARATION

-

Page/Page column 11, (2011/10/03)

The present invention provides for highly pure mosapride citrate dihydrate and processes for its preparation. The present invention further provides a process for the preparation of mosapride citrate dihydrate substantially free of impurity D-II.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 112885-42-4